| Detected | Trial | Change |
|---|---|---|
| 2026-07-25 | NCT03478514 Phase II Palbociclib +Ibrutinib in Mantle Cell Lymphoma |
date change Primary completion pushed: 2025-11-10 -> 2025-12-19 |
| NCT ID | Title | Condition | Status |
|---|---|---|---|
| Phase 3 | |||
| NCT02947685 | Randomized, Open Label, Clinical Study of the Targeted Therapy, Palbociclib, to Treat… | HER-2 Positive Breast Cancer | Active, Not Recruiting |
| NCT02513394 | PALbociclib CoLlaborative Adjuvant Study | Breast Cancer | Active, Not Recruiting |
| Phase 2 | |||
| NCT07149363 | Adjuvant Chemotherapy and Immunotherapy for Completely Resected Small Cell Lung Cancer | Small Cell Lung Cancer (SCLC) | Recruiting |
| NCT04062708 | CHIO3 Trial: CHemotherapy Combined With Immune Checkpoint Inhibitor for Operable Stage… | Stage IIIA Non-small Cell Lung Cancer | Active, Not Recruiting |
| NCT04009109 | Study of Lenalidomide/Ixazomib/Dexamethasone/Daratumumab in Transplant-Ineligible… | Myeloma, Multiple | Active, Not Recruiting |
| NCT05798663 | Atezolizumab Immunotherapy With or Without Tiragolumab for Patients With Unresectable… | NSCLC | Active, Not Recruiting |
| NCT03478514 | Phase II Palbociclib +Ibrutinib in Mantle Cell Lymphoma | Mantle Cell Lymphoma | Active, Not Recruiting |
| Phase 1/2 | |||
| NCT04486352 | A Study of Targeted Agents for Patients With Recurrent or Persistent Endometrial Cancer | Endometrial Cancer | Recruiting |
| Not specified | |||
| NCT06963723 | Longitudinal Screening for Financial Hardship to Improve Outcomes in Patients With… | Advanced Cancer | Recruiting |
| NCT02926911 | Comparing an Operation to Monitoring, With or Without Endocrine Therapy (COMET) Trial For… | DCIS | Active, Not Recruiting |